137 related articles for article (PubMed ID: 35348710)
1. Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer.
Zhuo N; Liu C; Zhang Q; Li J; Zhang X; Gong J; Lu M; Peng Z; Zhou J; Wang X; Jiao X; Wang Y; Wang Y; Gao M; Shen L; Lu Z
JAMA Netw Open; 2022 Mar; 5(3):e224637. PubMed ID: 35348710
[TBL] [Abstract][Full Text] [Related]
2. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
3. Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients.
Heo JY; Yoo SH; Suh KJ; Kim SH; Kim YJ; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Sci Rep; 2021 Jan; 11(1):2514. PubMed ID: 33510255
[TBL] [Abstract][Full Text] [Related]
4. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Xu Y; Li H; Fan Y
Front Oncol; 2021; 11():642883. PubMed ID: 33747966
[TBL] [Abstract][Full Text] [Related]
5. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
[TBL] [Abstract][Full Text] [Related]
6. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Matsumoto H; Hirano K; Kominami R; Tomii K; Suzuki H; Hirashima T; Tanaka S; Uchida J; Morita M; Kanazu M; Mori M; Nagata K; Fukuda I; Tamiya M
BMC Cancer; 2021 Apr; 21(1):346. PubMed ID: 33794809
[TBL] [Abstract][Full Text] [Related]
7. Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Sindhu KK; Leiter A; Moshier E; Lin JY; Carroll E; Brooks D; Shimol JB; Eisenberg E; Gallagher EJ; Stock RG; Galsky MD; Buckstein M
Cancer Treat Res Commun; 2020; 25():100216. PubMed ID: 33049542
[TBL] [Abstract][Full Text] [Related]
8. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
11. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
12. Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer.
Lu Z; Zou J; Hu Y; Li S; Zhou T; Gong J; Li J; Zhang X; Zhou J; Lu M; Wang X; Peng Z; Qi C; Li Y; Li J; Li Y; Zou J; Du X; Zhang H; Shen L
JAMA Netw Open; 2019 Jul; 2(7):e197621. PubMed ID: 31339548
[TBL] [Abstract][Full Text] [Related]
13. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
16. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
18. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
[TBL] [Abstract][Full Text] [Related]
19. Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer.
Yu X; Chu X; Wu Y; Zhou J; Zhao J; Zhou F; Han C; Su C
Cancer Drug Resist; 2021; 4(3):728-739. PubMed ID: 35582303
[No Abstract] [Full Text] [Related]
20. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
